These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 34174139)

  • 41. Pyridoxamine lowers kidney crystals in experimental hyperoxaluria: a potential therapy for primary hyperoxaluria.
    Chetyrkin SV; Kim D; Belmont JM; Scheinman JI; Hudson BG; Voziyan PA
    Kidney Int; 2005 Jan; 67(1):53-60. PubMed ID: 15610227
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tolvaptan to prevent calcium oxalate crystal deposition in the kidney allograft after kidney transplantation for primary hyperoxaluria.
    Stehlé T; Letavernier E; Joher N; Mesnard L; Moktefi A; Matignon M
    Kidney Int; 2023 Aug; 104(2):398. PubMed ID: 37479387
    [No Abstract]   [Full Text] [Related]  

  • 43. Urinary monocyte chemoattractant protein 1 associated with calcium oxalate crystallization in patients with primary hyperoxaluria.
    Wang X; Bhutani G; Vaughan LE; Enders FT; Haskic Z; Milliner D; Lieske JC;
    BMC Nephrol; 2020 Apr; 21(1):133. PubMed ID: 32293313
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Continuous infusion of oxalate by minipumps induces calcium oxalate nephrocalcinosis.
    Marengo SR; Chen DH; Evan AP; Sommer AJ; Stowe NT; Ferguson DG; Resnick MI; MacLennan GT
    Urol Res; 2006 Jun; 34(3):200-10. PubMed ID: 16479391
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Transplantation outcomes in primary hyperoxaluria.
    Bergstralh EJ; Monico CG; Lieske JC; Herges RM; Langman CB; Hoppe B; Milliner DS;
    Am J Transplant; 2010 Nov; 10(11):2493-501. PubMed ID: 20849551
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pathophysiological correlates of two unique renal tubule lesions in rats with intestinal resection.
    Worcester E; Evan A; Bledsoe S; Lyon M; Chuang M; Orvieto M; Gerber G; Coe F
    Am J Physiol Renal Physiol; 2006 Nov; 291(5):F1061-9. PubMed ID: 17028259
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical and Metabolic Correlates of Calcium Oxalate Stone Subtypes: Implications for Etiology and Management.
    Bamberger JN; Blum KA; Kan KM; Parkhomenko E; Gallante B; Gupta M
    J Endourol; 2019 Sep; 33(9):755-760. PubMed ID: 31154910
    [No Abstract]   [Full Text] [Related]  

  • 48. Hydroxycitric Acid Tripotassium Inhibits Calcium Oxalate Crystal Formation in the Drosophila Melanogaster Model of Hyperoxaluria.
    Han S; Zhao C; Pokhrel G; Sun X; Chen Z; Xu H
    Med Sci Monit; 2019 May; 25():3662-3667. PubMed ID: 31099342
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Lost in Transportation: Calcium Oxalate Crystals in Kidney Biopsy Specimens Fixed in Michel Medium May Disappear.
    Cassol CA; Braga JR; Hartage R; Satoskar AA; Nadasdy T; Brodsky SV
    Arch Pathol Lab Med; 2020 Apr; 144(4):485-489. PubMed ID: 31403332
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The clinical significance of assessment of serum calcium oxalate saturation in the hyperoxaluria syndromes.
    Marangella M; Vitale C; Petrarulo M; Linari F
    Nephrol Dial Transplant; 1995; 10 Suppl 8():11-3. PubMed ID: 8592617
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Calcium oxalate supersaturation increases early after Roux-en-Y gastric bypass.
    Agrawal V; Liu XJ; Campfield T; Romanelli J; Enrique Silva J; Braden GL
    Surg Obes Relat Dis; 2014; 10(1):88-94. PubMed ID: 23953730
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Early changes of oxalate and calcium urine excretion in those with calcium oxalate stone formation after extracorporeal shock wave lithotripsy.
    Oehlschläger S; Albrecht S; Hakenberg OW; Schrödter S; Froehner M; Manseck A; Wirth MP
    Urology; 2003 Jul; 62(1):17-21. PubMed ID: 12837412
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Reversal of Roux-en-Y Gastric Bypass for Successful Salvage of Renal Allograft.
    Hrebinko K; Moroni E; Ganoza A; Puttarajappa CM; Molinari M; Sood P; El Hag M; Wijkstrom M; Tevar AD
    Am Surg; 2023 Apr; 89(4):1286-1289. PubMed ID: 33631945
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Modeling of hyperoxaluric calcium oxalate nephrolithiasis: experimental induction of hyperoxaluria by hydroxy-L-proline.
    Khan SR; Glenton PA; Byer KJ
    Kidney Int; 2006 Sep; 70(5):914-23. PubMed ID: 16850024
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Structural and chemical heterogeneities of primary hyperoxaluria kidney stones from pediatric patients.
    Du Y; Roger VB; Mena J; Kang M; Stoller ML; Ho SP
    J Pediatr Urol; 2021 Apr; 17(2):214.e1-214.e11. PubMed ID: 33495102
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pathophysiology and Management of Hyperoxaluria and Oxalate Nephropathy: A Review.
    Demoulin N; Aydin S; Gillion V; Morelle J; Jadoul M
    Am J Kidney Dis; 2022 May; 79(5):717-727. PubMed ID: 34508834
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Magnesium, citrate, magnesium citrate and magnesium-alkali citrate as modulators of calcium oxalate crystallization in urine: observations in patients with recurrent idiopathic calcium urolithiasis.
    Schwille PO; Schmiedl A; Herrmann U; Fan J; Gottlieb D; Manoharan M; Wipplinger J
    Urol Res; 1999 Apr; 27(2):117-26. PubMed ID: 10424393
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Studies on the role of calcium phosphate in the process of calcium oxalate crystal formation.
    Tiselius HG; Lindbäck B; Fornander AM; Nilsson MA
    Urol Res; 2009 Aug; 37(4):181-92. PubMed ID: 19444436
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of angiotensin II receptor blockage on osteopontin expression and calcium oxalate crystal deposition in rat kidneys.
    Umekawa T; Hatanaka Y; Kurita T; Khan SR
    J Am Soc Nephrol; 2004 Mar; 15(3):635-44. PubMed ID: 14978165
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Primary hyperoxaluria diagnosed after kidney transplant: A review of the literature and case report of aggressive renal replacement therapy and lumasiran to prevent allograft loss.
    Stone HK; VandenHeuvel K; Bondoc A; Flores FX; Hooper DK; Varnell CD
    Am J Transplant; 2021 Dec; 21(12):4061-4067. PubMed ID: 34254430
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.